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REGISTERED REPORT

Registered report: IDH mutation impairs
histone demethylation and results in a
block to cell differentiation
Adam D Richarson1, David A Scott1, Olga Zagnitko1, Pedro Aza-Blanc2,
Chih-Cheng Chang2, David A Russler-Germain3,
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of Medicine, St Louis, United States

Abstract The Reproducibility Project: Cancer Biology seeks to address growing concerns about
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reproducibility in scientific research by conducting replications of selected experiments from a
number of high-profile papers in the field of cancer biology. The papers, which were published
between 2010 and 2012, were selected on the basis of citations and Altmetric scores (Errington
et al., 2014). This Registered Report describes the proposed replication plan of key experiments
from “IDH mutation impairs histone demethylation and results in a block to cell differentiation” by
Lu and colleagues, published in Nature in 2012 (Lu et al., 2012). The experiments that will be
replicated are those reported in Figures 1B, 2A, 2B, 2D and 4D. Lu and colleagues demonstrated
that expression of mutant forms of IDH1 or IDH2 caused global increases in histone methylation
and increased levels of 2 hydroxyglutarate (Figure 1B). This was correlated with a block in
differentiation (Figures 2A, B and D). This effect appeared to be mediated by the histone
demethylase KDM4C (Figure 4D). The Reproducibility Project: Cancer Biology is a collaboration
between the Center for Open Scienceand Science Exchange, and the results of the replications will
be published by eLife.
DOI: 10.7554/eLife.10860.001
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Introduction
Mutations in the metabolic proteins IDH1 and IDH2 are associated with gliomas, acute myeloid leukemias, chondrosarcomas, intrahepatic cholangiocarcinomas, lymphomas, melanomas and colon,
thyroid and prostate cancers (for review, see Krell et al., 2013). Previous work has shown that these
mutations change the specificity of the reaction catalyzed by IDH proteins; instead of producing aketoglutarate from isocitrate, they produce 2-hydroxyglutarate (2HG), a metabolite that can have
oncogenic effects (Krell et al., 2013; McKenney and Levine, 2013; Ward et al., 2010; Xu et al.,
2011; Zhang et al., 2013). Lu and colleagues expand upon this work to identify a potential mechanism for how 2HG can effect major changes in cell behavior. They present evidence that 2HG interferes with global demethylation that is required for progenitor cells to complete terminal
differentiation. Transfection of 3T3-L1 cells with the mutant forms of IDH1 and IDH2 that produce
2HG lead to an increase in global methylation levels and prevented normal in vitro differentiation
into adipocytes. The 2HG-sensitive histone demethylase KDM4C appeared to be required for this
process, as knockdown of KDM4C recapitulated the phenotype of 2HG production. Examination of
glioma samples showed a correlation between IDH mutation status and level of overall methylation
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(Lu et al., 2012). Taken together, Lu and colleagues’ findings help explain how mutations in IDH1
and IDH2 potentially interface with cancer development and progression.
In Figure 1B, Lu and colleagues examined the effects of mutations in IDH1 and IDH2 on global
levels of methylation by transfecting mutant and wild type forms of the genes into 293T cells and
using Western blot to assess the levels of various methylation markers. They also confirmed that
introduction of the mutated forms of IDH1 and IDH2 correlated with increased intracellular levels of
the oncometabolite 2HG. Their findings suggest that mutations in IDH1 and IDH2 correlate with
increased levels of many methylation markers, and this key finding is replicated in Protocol 1.
In order to understand the effects of hypermethylation more fully, Lu and colleagues turned to an
in vitro model of differentiation; when treated with appropriate signals, 3T3-L1 cells undergo epigenetic changes required for them to differentiation into adipocytes. In Figure 2A and B, they transfect
undifferentiated 3T3-L1 cells with the wild type and mutant forms of IDH2 and assess the cells’ ability
to differentiate into adipocytes, as determined by staining for lipid droplets with Oil-Red-O. While
differentiated 3T3-L1 cells transfected with vector only or wild type IDH2 showed robust Oil-Red-O
staining, cells transfected with mutant IDH2 did not, indicating a block in differentiation. qRT-PCR
confirmed that cells transfected with mutant IDH variants did not express high levels of known adipocyte markers (Figure 2D). This key finding will be replicated in Protocol 2.
Lu and colleagues identified a histone demethylase, KDM4C, expressed as 3T3-L1 differentiation
progressed, that appeared to be sensitive to 2HG. In Figure 4D, they use siRNAs to knock down levels of KDM4C in differentiating 3T3-L1 cells. Western blot analysis and Oil-Red-O staining confirmed
that loss of KDM4C increased global methylation levels and inhibited differentiation. This key finding
will be replicated in Protocol 3.
Several aspects of Lu’s findings have been corroborated by other work. Multiple groups have
demonstrated that perturbations in IDH proteins alter methylation levels; overexpression of the
IDH1R132H allele in human tumor cells lines increased global histone methylation levels
(Duncan et al., 2012), exogenous IDH2R140Q increased methylation levels in erythroleukemia progenitor cells (Kernytsky et al., 2015) and an immortalized astrocyte cell line expressing IDH1R132H
also demonstrated increased levels of methylation (Turcan et al., 2012). Members of the Thompson
lab (authors of this study) have confirmed that expression of mutant variants of IDH proteins in 3T3L1 cells blocked differentiation into adipocytes (Londono Gentile et al., 2013; Ward et al., 2013).
Sasaki and colleagues have shown that mutant IDH1 expression increased levels of methylation in
mice (Sasaki et al., 2012), while Akbay and colleagues published a similar observation for mutant
forms of IDH2 (Akbay et al., 2014). This effect may even hold true for human patients, as there is a
marked increase in H3K9me3 levels associated with IDH mutations in oligodendromas and high
grade astrocytomas (Venneti et al., 2013).

Materials and methods
Unless otherwise noted, all protocol information was derived from the original paper, references
from the original paper, or information obtained directly from the authors. An asterisk (*) indicates
data or information provided by the Reproducibility Project: Cancer Biology core team. A hashtag
(#) indicates information provided by the replicating lab.

Protocol 1: Assessing the methylation status and 2HG production of
293T cells transfected with mutant forms of IDH1 and IDH2
This protocol describes how to transfect 293T cells with wild-type and mutant forms of IDH1 and
IDH2 and assess levels of global methylation and 2HG production, as seen in Figure 1B and Supplemental Figure 1.

Sampling
.

Experiment will be repeated a total of 6 times for a minimum power of 80%. The metabolite
data is qualitative, thus to determine an appropriate number of replicates to initially perform,
sample sizes based on a range of potential variance was determined.
 See "power alculations’ for details.
 The metabolite data displayed in the bottom of Figure 1B were derived from Figure 3B of
Figueroa and colleagues (Figueroa et al., 2010).
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Each experiment consists of five cohorts:
 Cohort 1: 293T cells transfected with vector only
 Cohort 2: 293T cells transfected with wild-type IDH1
 Cohort 3: 293T cells transfected with IDH1R132H
 Cohort 4: 293T cells transfected with wild type IDH2
 Cohort 5: 293T cells transfected with IDH2R172K
Each cohort is then examined for methylation status by Western blot and levels of 2HG production by GC-MS.

Materials and reagents
Reagent

Type

Manufacturer

Catalog #

Comments

10 cm tissue culture dishes

Labware

Thermo Scientific

130182

Original unspecified

Bradford Assay Kit

Reporter assay

Bio-Rad

500-0201EDU

Original unspecified

DMEM

Cell culture

Corning

15013 CV

Replaces original from Invitrogen

Endo-free plasmid maxiprep kit

Kit

Qiagen

12362

Original unspecified

Fetal bovine serum (FBS)

Cell culture

CellGro

10437-028

Original cat # unspecified

293T cells

Cell line

ATCC

CRL-3216

Original source unspecified

HRP-conjugated donkey
anti-rabbit secondary

Antibody

GE Healthcare

NA934V

HRP-conjugated sheep
anti-mouse secondary

Antibody

GE Healthcare

NA931V

IDH1 ORF clone

Nucleic acid

OriGene

RC210582

Replaces ATCC plasmid
in pCMV-Sport6

IDH1R132H ORF clone

Nucleic acid

OriGene

RC400096

Original generated
by authors

IDH2 ORF clone

Nucleic acid

OriGene

RC201152

Replaces Invitrogen
plasmid in pOTB7

IDH2R172K ORF clone

Nucleic acid

OriGene

RC400103

Original generated
by authors

Mouse IgG1 monoclonal
anti-IDH2

Antibody

Abcam

Ab55271

Nitrocellulose
membrane

Western blot reagent

Life Technologies

LC2006

Nonfat milk

Western blot reagent

Carnation

NuPAGE 4-12% precast
gradient gel

Western blot reagent

Invitrogen

WG1401BOX

Original source unspecified

PierceÔ ECL Plus
Western Blotting Substrate

Western blot reagent

Life Technologies

32132

Original unspecified

pLPC vector plasmid
(pLPC H-Ras V12)

Nucleic acid

Addgene

18741

Original source unspecified

Ponceau stain

Chemical

SIGMA

P7170-1L

Original unspecified

Protease Inhibitor
Cocktail,

Inhibitor

Sigma-Aldrich

P8340

Original unspecified

Rabbit IgG monoclonal
anti-H3

Antibody

Cell Signaling Technology

4499

Rabbit monoclonal
anti-H3K4me3

Antibody

Millipore

17-614

Rabbit polyclonal
anti-H3K36me3

Antibody

Abcam

Ab9050

Rabbit polyclonal
anti-H3K79me2

Antibody

Cell Signaling Technology

9757

Original source unspecified
Original source unspecified

Continued on next page
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Continued
Reagent

Type

Manufacturer

Catalog #

Comments

Rabbit polyclonal
anti-H3K9me2

Antibody

Cell Signaling Technology

9753

Rabbit polyclonal
anti-H3K9me3

Antibody

Abcam

Ab8898

Rabbit polyclonal
anti-IDH1

Antibody

ProteinTech

12332-1-AP

TBS + Tween 20

Buffer

Fisher Scientific

BP-2471-1

Original source unspecified

XCell II blot module

Instrument

Life Technologies

EI9051

Original unspecified

Acetonitrile, HPLC
grade

Chemical

Spectrum

HP412

Original source unspecified

Chloroform

Chemical

Fisher

C606-4

Original unspecified

D-alpha-hydroxyglutaric
acid disodium salt (2HG)

Chemical

Santa Cruz Biotechnology

Sc-227739

Replaces original from Sigma

Methanol, HPLC grade

Chemical

MP

300141

Original source unspecified

N-methyl-N-tert-butyldimethylsilyl
trifluoroacetamide (MTBSTFA)

Chemical

Soltec Ventures

GC102

Replaces original
from Regis

Norvaline

Chemical

Sigma

N7627

Original unspecified

Protein Concentration
Assay; Quick Start
Bradford Assay

Reporter assay

Bio-Rad

500-0205

Original unspecified

Lipofectamine 2000

Cell culture

Life Technologies

11668027

Original cat # unspecified

Procedure
Note: 293T cells are maintained in DMEM with 10% FBS at 37˚C/5% CO2 All cells will be sent for
STR profiling and mycoplasma testing.
.

.
.

.

.

Using the pLPC backbone and the OriGene ORF clones, clone in the sequences for wild-type
IDH1, wild-type IDH2, IDH1R132H or IDH2R172K to generate the following vectors:
1. pLPC-IDH1
2. pLPC-IDH2
3. pLPC-IDH1R132H
4. pLPC-IDH2R172K
Prep each vector using an endo-free maxiprep kit according to the manufacturer’s instructions.
Confirm plasmid identity by sequencing insert and vector integrity by agarose gel
electrophoresis.
1. Note; OriGene ORF clones are shipped with sequencing primers.
Plate 293T cells in #10 cm tissue culture dishes and let adhere overnight.
1. Plate two plates; one will be harvested for Western blot (Step 3), the other for metabolite
analysis (Step 4).
Transfect 293T cells with appropriate plasmids with Lipofectamine 2000 according to the manufacturer’s instructions.
1. Note: Prepare separate transfection mixtures for each replicate, then use the same mixture for all plates within that replicate; do not use a single large volume for transfection
mixture for all replicates.
a. pLPC (empty vector)
b. pLPC-IDH1
c. pLPC-IDH2
d. pLPC-IDH1R132H
e. pLPC-IDH2R172K
2. Incubate for 3 days.
a. At this point, the matched plates for each replicate will be harvested; one plate for
Western blot analysis (Step 6), the matched plate for GC-MS analysis (Step 7).
3. Note; from this point forward, the analysis of each replicate must be conducted separately
and independently from the other replicates. For example, each replicate should be run
on its own gels.
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Western blot analysis of methylation status:
1. Acid extraction of histones:
a. Lyse cells in hypotonic lysis buffer for 1.
i. Hypotonic lysis buffer: 10mM HEPES, 10mM KCl, 1.5mM MgCl2, 0.5mM DTT,
#
protease inhibitor cocktail
b. Add H2SO4 to 0.2N and incubate at 4˚C overnight with rotation.
c. #Centrifuge samples at 6,500xg for 10min at 4˚C to pellet debris.
d. Precipitate proteins with 33% TCA.
e. Wash with acetone.
f. Resuspend in de-ionized water.
2. *#Quantify protein concentration using a Bradford Assay.
3. #Load ~ 50 mg of protein per well and separate proteins on a 10% NuPAGE 4-12% gradient gel.
4. #Transfer to nitrocellulose membrane using an XCell II blot module at 25 V for 1-2 hr
(start at 100 mA per gel).
5. *Perform a Ponceau stain and image to confirm transfer of proteins.
a. Wash out Ponceau.
6. Block membrane for #1 hr in 5% non-fat milk in PBS with 0.5% Tween-20.
7. Incubate with primary antibodies #diluted in TBST + 1% nonfat milk at 4˚C overnight.
*
Use the manufacturer’s recommended dilution.
a. Anti-IDH1
b. Anti-IDH2
c. Anti-H3K4me3
d. Anti-H3K9me2
e. Anti-H3K9me3
f. Anti-H3K36me3
g. Anti-H3K79me2
h. Anti-H3 (loading control)
i. #Each antibody will have its own gel run. Membranes will not be stripped and
reprobed.
8. Wash membrane #twice with TBST for a total of 20 min.
a. Incubate with HRP-conjugated secondary antibodies #diluted in TBST for 1 hr at
room temperature. #*Use manufacturer recommended dilutions.
9. Wash three times with TBST.
10. Detect signal #using ECL plus according to the manufacturer’s instructions.
11. Quantify band intensities with ImageJ.
a. Normalize methylation band intensities to total H3.
b. Divide normalized band intensities by the vector control band intensity.
Gas chromatography-mass spectrometry analysis of 2HG levels. Note; the data in the original
paper and the methodology are derived from Figueroa and colleagues (Figueroa et al.,
2010).
1. Gently remove culture medium from cells 3 days after transfection, #wash cells quickly
three times with 2 ml ice-cold PBS, and add #0.5 ml ice-cold 80% methanol containing
20 mM L-norvaline per well of a 6-well plate to the cells.
a. #Quantify protein concentration using the #Bio-Rad Quick Start Bradford Assay.
2. Incubate 20 min at -80˚C.
3. Centrifuge at 14000xg for 20 min at 4˚C.
a. #Counter-extract samples with chloroform to remove nonpolar metabolites.
4. Collect supernatant and dry using a #MiVac.
5. Redissolve dried extracts in #60 mL of a 1:1 mixture of acetonitrile and N-methyl-N-tertbutyldimethylsilyltrifluoroacetamide (MTBSTFA).
6. Heat the samples for 75 min at 70˚C.
7. GC-MS analysis:
a. #A Shimadzu QP2010 Plus GC-MS is programmed with an injection temperature of
250˚C, injection split ratio 1/10, with injection volume 0.3-1 ml. GC oven temperature
starts at 130˚C for 4 min, rising to 243˚C at 6˚C/min and to 280˚C at 60˚C/min with a
final hold at this temperature for 2 min. GC flow rate with helium carrier gas was 50
cm/s. The GC column used is a 15 m x 0.25 mm x 0.25 mm Rxi-5ms (Restek). GC-MS
interface temperature is 300˚C and (electron impact) ion source temperature is
200˚C, with 70 V/ 70 mA ionization voltage/ current. The mass spectrometer is set to
scan m/z range 150-600, with ~1 kV detector sensitivity (modified as necessary).
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8. *#In parallel to the sample, run a standard curve of known amounts of 2HG.
9. Confirm and *#quantify 2HG metabolite peak using standard curve.
10. Analyze and *#quantify 2HG and glutamate signal (identified by elution time and mass
fragment pattern) intensities by integration of peak areas.
Repeat independently from Step 4 onwards an additional five times.

Deliverables
.

Data to be collected:
 Sequence files and agarose gel images confirming vector identity
 Full gel images of western blots with ladder (as seen in Figure 1B)
&
Images of Ponceau stained membranes
 Quantification of band intensities (as seen in Supplemental Figure 1A)
 GC-MS data
 Quantification of signal intensities of 2HG and glutamate (as seen in Figure 1B)

Confirmatory analysis plan
.

.

.

Statistical Analysis of the Replication Data:
Note: At the time of analysis we will calculate Pearson’s r to check for correlation between
the six dependent variables, normalized intensities measured for each of the histone lysine
methylations, for the Western blot data. We will also perform the Shapiro-Wilk test and generate a quantile-quantile plot to assess the normality of the Western blot data and 2HG/glutamate ratios. We will also perform Levene’s test to assess homoscedasticity. If the data
appear skewed we will perform a log transformation in order to proceed with the proposed
statistical analysis. If the log transformation does not result in similar variance across groups,
we will perform the equivalent non-parametric test listed in Power Calculations for this
protocol.
 Western blot:
&
MANOVA (six dependent variables are the normalized intensities for each of the
histone lysine methylations; four independent variables are the IDH1 and IDH2 variants (all normalized to vector) with the following planned comparisons using Bonferroni’s correction:
. Wild-type IDH1 compared to IDH1R132H, for H3K9me2.
. Wild-type IDH2 compared to IDH2R172K, for H3K9me2.
 2HG/glutamate ratios:
&
One-way ANOVA (one dependent variable is the 2HG/glutamate ratio; four independent variables are the IDH1 and IDH2 variants) with the following planned comparisons using Bonferroni’s correction:
&
IDH1WT compared to IDH1R132H
&
IDH2WT compared to IDH2R172K
Meta-analysis of original and replication attempt effect sizes:
 For Western blot:
&
The replication attempt will perform the statistical analysis listed above, compute
the effects sizes, compare them against the reported effect size in the original
paper and use a meta-analytic approach to combine the original and replication
effects, which will be presented as a forest plot.
 For 2HG/glutamate ratios:
&
The replication data will be presented as a mean with 95% confidence intervals and
will include the original data point, calculated directly from the representative
image, as a single point on the same plot for comparison.
Additional exploratory analysis:
 Correlation analysis (Pearson’s r) of each of the six relative histone methylation levels to
2HG/glutamate levels using Bonferroni ‘s correction (as seen in Supplemental Figure 1B).
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Known differences from the original study
.

.

The replication attempt will quantify total amounts of 2HG in addition to the ratio of 2HG to
glutamate.
Aspects of the Western blot protocol are provided by the replicating lab; complete details of
the original protocol were unavailable.

Provisions for quality control
All data obtained from the experiment - raw data, data analysis, control data and quality control
data - will be made publicly available, either in the published manuscript or as an open access dataset available on the Open Science Framework (https://osf.io/vfsbo/).
.
.
.

Sequence files and agarose gel images confirming vector identity and integrity
Ponceau stains confirming protein transfer to membranes
STR profiling and mycoplasma testing results

Protocol 2: Examining the effects of mutations in IDH2 on
differentiation of 3T3-L1 cells
This protocol describes how to induce the differentiation of 3T3-L1 cells into adipocytes, which
involves extensive chromatin remodeling, after transfection with wild type and mutant forms of IDH2
and assess the level of differentiation by Oil-Red-O staining, as seen in Figure 2A and B, and adipocyte marker expression, as seen in Figure 2D.

Sampling
.

.

.

This experiment will use 5 biological replicates for a minimum power of 80%. The metabolite
data is qualitative, thus to determine an appropriate number of replicates to initially perform,
sample sizes based on a range of potential variance was determined.
 See Power Calculations for details.
Each experiment will consist of three cohorts:
 Cohort 1: 3T3-L1 cells transduced with vector
 Cohort 2: 3T3-L1 cells transduced with wild-type IDH2
 Cohort 3: 3T3-L1 cells transduced with IDH2R172K
Each cohort will have 5 plates per biological replicate:
 One plate will be used to assess IDH2 expression by Western blot.
 The second plate will be used to assess intracellular levels of 2HG.
 The third plate will be assessed for adipogenesis by Oil-Red-O staining.
 The fourth and fifth plates will have mRNA harvested for qRT-PCR analysis.

Materials and reagents
Reagent

Type

Manufacturer

Catalog #

Comments

Isobutylmethylxanthine

Inhibitor

Sigma

I5879

Original cat# unspecified

Dexamethasone

Chemical

Sigma

D4902

Original cat# unspecified

Insulin

Growth factor

Sigma

I3536

Original cat# unspecified

Troglitazone

Chemical

Sigma

T2573

Original cat# unspecified

pCL-Eco helper plasmid

Nucleic acid

Addgene

12371

Original source unspecified

293T cells

Cell line

ATCC

CRL-3216

Original source unspecified

3T3-L1 cells

Cell line

ATCC

CL-173

Original source unspecified

Puromycin

Chemical

Life Technologies

A11138-02

Original unspecified

RIPA buffer

Cell culture

Millipore

20188

Original source unspecified

Nitrocellulose membrane

Western blot reagent

Life Technologies

LC2006

Original source unspecified

Continued on next page

Richarson et al. eLife 2016;5:e10860. DOI: 10.7554/eLife.10860

7 of 25

Registered report

Human biology and medicine

Continued
Reagent

Type

Manufacturer

Catalog #

Comments
Original source unspecified

Ponceau stain

Chemical

Sigma

P7170

Rabbit polyclonal anti-IDH1

Antibody

ProteinTech

12332-1-AP

Mouse IgG1 monoclonal anti-IDH2

Antibody

Abcam

Ab55271

HRP-conjugated donkey anti-rabbit secondary

Antibody

GE Healthcare

NA934V

HRP-conjugated sheep anti-mouse secondary

Antibody

GE Healthcare

NA931V

Oil-Red-O

Chemical

Sigma

O1391

Original source unspecified

paraformaldehyde

Chemical

Tousimis

1008A

Original source unspecified

6-well tissue culture plates

Labware

Sarstedt

83.1839

Original unspecified

XtremeGene HP reagent

Cell culture

Roche

06366244001

Original unspecified

DMEM

Cell culture

Corning

15013 CV

Replaces original from
Invitrogen

FBS

Cell culture

CellGro

10437-028

Original cat # unspecified

OPTI-MEM

Cell culture

Life Technologies

31986070

Original unspecified

0.45 mm low binding syringe filter

Labware

Millipore

SLHV013SL

Original unspecified

Endo-free maxiprep kit

Kit

Qiagen

12362

Original unspecified

Protein Concentration Assay;
Quick Start Bradford Assay

Reporter assay

Bio-Rad

500-0205

Original unspecified

Spectrophotometer

Instrument

Beckman Coulter

DU800

Original unspecified

TRIzol

Chemical

Invitrogen

15596-018

Original cat# unspecified

SuperScript II reverse transcriptase

Kit

Invitrogen

18064-014

Original cat# unspecified

7900HT Sequence Detection System

Instrument

Applied Biosystems

Pparg Taqman assays; Hs00234592_m1

Nucleic acid

Applied Biosystems

Cat. # 4351372

Original assay unspecified

Cebpa Taqman assays; Hs00269972_s1

Nucleic acid

Applied Biosystems

Cat. # 4331182

Original assay unspecified

Adipoq Taqman assays; Hs00605917_m1

Nucleic acid

Applied Biosystems

Cat. # 4331182

Original assay unspecified

18S rRNA Taqman assays; Hs99999901_s1

Nucleic acid

Applied Biosystems

Cat. # 4331182

Original assay unspecified

Procedure
Note: 3T3-L1 and 293T cells are maintained in DMEM with 10% FBS at 37˚C/5% CO2 .All cells will be
sent for STR profiling and mycoplasma testing. pLPC (empty vector), pLPC-IDH2, and pLPCIDH2R172K are generated in Protocol 1.
.

.

Generate vector and IDH2 wild type and mutant expressing retroviruses.
1. #Transfect 293T cells with pCL-Eco helper plasmid and vector or IDH2 vectors.
a. Spot virus construct in 6 well plates at 1000 ng/well.
b. Perform X-tremeGeneHP reverse transfection as follows:
i. Make the helper plasmid mix; 700 ng/well.
ii. Add 4 mL of XtremeGene HP to 400 mL OPTI-MEM.
. Mix by light tapping.
iii. Mix together the helper plasmids with the XtremeGeneHP reagent and OPTIMEM.
iv. Add 400 mL of the mix to each well and incubate for at least 30 min at room
temperature.
v. Meanwhile, resuspend 293T cells in DMEM + 10% FBS at 1.2x106 cells/ml.
vi. Add 1600 mL of cells to each well.
2. #24 hr later, replace media (2 ml total).
3. #48 hr post transfection, collect supernatant from each well.
a. Centrifuge at 500xg for 10 min at room temperature to pellet debris.
b. Filter supernatant through a 0.45 mm syringe filter, aliquot and store at -80˚C.
Transduce 3T3-L1 cells with viral supernatant.
1. #Seed cells in 6-well plates and incubate overnight.
a. Cells should be 50-60% confluent the next day.
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.

.

.

.

.

.

2. #Add viral supernatant to medium.
a. Supernatant will be added at varying concentrations to determine optimal transduction efficiency; 1:5 to 1:10 – 150 to 300 mL per well.
3. #Adjust media volume to 1.4 ml per well.
4. #Add polybrene in 100 mL of media into each well for a final concentration of 8 mg/ml.
5. #Spinoculate by spinning at 1000xg for 60 min at room temperature.
a. Incubate overnight.
6. #Change media to remove viral transduction media.
a. Replace with fresh media.
7. Grow cells with 2.5 mg/ml puromycin for 7 days to select for stable expression of either
wild-type or mutant IDH2.
a. Maintain cells in puromycin.
b. Also treat a non-transduced well of 3T3-L1 cells as a control showing susceptibility
to puromycin.
c. Split each biological replicate into 5 plates for the four assays being performed.
i. Plate 1 is for Western blot
ii. Plate 2 is for GC-MS
iii. Plate 3 is for Oil-Red-O staining (harvested 7 days after differentiation)
iv. Plate 4 and 5 are for qRT-PCR (harvested 0 and 4 days after differentiation)
Generate whole cell lysates from the first plate of each cohort:
1. Lyse cells and sonicate in RIPA buffer.
a. RIPA buffer: 1% sodium deoxycholate, 0.1% SDS, 1% Triton X-100, 0.01 M Tris pH
8.0 and 0.14 M NaCl
b. #Sonicate for 1 min, at 180 watts with rounds of 10 sec on/10 sec off. Keep sample
on ice during sonication.
2. Centrifuge lysates at 14000xg for 10 min at 4˚C.
3. Collect supernatant and measure total protein concentration #using a Bradford assay.
4. Perform Western blot as outlined in Protocol 1 Step 6 using the following primary antibodies *at the manufacturer’s recommended dilution:
a. Anti-IDH1
b. Anti-IDH2
Harvest the second plate for metabolite analysis by mass spectrometry as described in Protocol 1 Step 4.
Induce 3T3-L1 cells to differentiate into adipocytes.
1. Incubate cells for 2 days with a differentiation cocktail composed of 0.5 mM isobutylmethylxanthine, 1 mM dexamethasone, 5 mg/ml insulin and 5 mM troglitazone supplementing the standard media.
2. After 3 days, maintain cells with 5 mg/ml insulin until harvested.
After 7 days of differentiation, assess adipogenesis by Oil-Red-O staining in the third plate
from each cohort.
1. Wash cells in PBS and fix in 3% paraformaldehyde for 20 min at room temperature.
2. Wash cells with de-ionized water.
3. Stain with Oil-Red-O solution according to the manufacturer’s protocol.
4. Image stained wells by brightfield microscopy and *quantify Oil-Red-O staining by
extracting oil-red-o in isopropanol and reading absorbance at 500 nm.
Harvest fourth plate for RNA extraction at Day 0 of differentiation and the fifth plate at Day 4
of differentiation and perform qRT-PCR to assess expression levels of adipocyte markers at
each time point.
1. Harvest cells and extract RNA using TRIzol according to the manufacturer’s instructions.
2. Reverse transcribe RNA and synthesize cDNA using SuperScript II reverse transcriptase
according to the manufacturer’s protocol.
a. Assess purity and concentration of RNA and cDNA spectrophotometrically; record
A260/A280 and A260/A230 ratios.
3. Perform qPCR on a 7900HT Sequence Detection system using Taqman gene expression
assays for the following genes:
a. Pparg
b. Cebpa
c. Adipoq
d. 18S rRNA for normalization.
i. *Primers sequences and PCR cycling conditions will be optimized.
Repeat independently from Step 2 onwards an additional four times.
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Deliverables
.

Data to be collected:
 Whole gel images of Western blots with ladder (as seen in Figure 2A)
 *Densitometric quantification of bands
&
Also normalized to the loading control.
 Images of wells stained with Oil-Red-O (as seen in Figure 2B)
 *Quantification of Oil-Red-O levels for each cohort
 All raw qRT-PCR data
 Graph of gene expression over time for each of the three adipocyte markers (as seen in
Figure 2D)

Confirmatory analysis plan
.

.

.

Statistical Analysis of the Replication Data:
Note: At the time of analysis we will calculate Pearson’s r to check for correlation between
the three dependent variables, normalized gene expression for each of the adipocyte
markers, for the qRT-PCR data. We will also perform the Shapiro-Wilk test and generate a
quantile-quantile plot to assess the normality of the qRT-PCR data and 2HG/glutamate ratios.
We will also perform Levene’s test to assess homoscedasticity. If the data appears skewed
we will perform a log transformation in order to proceed with the proposed statistical analysis. If this is not possible we will perform the equivalent non-parametric test listed in Power
Calculations for this protocol.
 Western Blot:
&
Confirmatory; no analysis performed
 2HG/glutamate ratio:
&
One-way ANOVA (one dependent variable is the 2HG/glutamate ratio; three independent variables are the vector and IDH2 variants) with the following planned
comparison using Fisher’s LSD correction:
. IDH2R172Kcompared to IDH2WT
 qRT-PCR:
&
One-way MANOVA (three dependent variables are the normalized gene expression
of each of the adipocyte markers on day 4; three independent variables are the
vector and IDH2 variants) with the following planned comparisons using Bonferroni’s correction:
. IDH2R172compared to vector for each gene (three comparisons total)
. IDH2R172Kcompared to IDH2WT for each gene (three comparisons total)
Meta-analysis of original and replication attempt effect sizes:
 For qRT-PCR:
&
The replication attempt will perform the statistical analysis listed above, compute
the effects sizes, compare them against the reported effect size in the original
paper and use a meta-analytic approach to combine the original and replication
effects, which will be presented as a forest plot.
 For 2HG/glutamate ratios:
&
The replication data will be presented as a mean with 95% confidence intervals and
will include the original data point, calculated directly from the representative
image, as a single point on the same plot for comparison.
Additional exploratory analysis:
 Oil-Red-O staining:
&
One-way ANOVA (one dependent variable is the A500 readings; three independent
variables are the vector and IDH2 variants) with the following planned comparison
using Fisher’s LSD correction:
. IDH2R172K compared to IDH2WT
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Known differences from the original study
.

.

.

Aspects of the Western blot protocol are provided by the replicating lab; complete details of
the original protocol were unavailable.
Aspects of the viral production protocol are adapted from the replicating lab’s in-house
protocol.
. Viral supernatant will be collected only at 48 hr post-transection and will not be combined with viral supernatant collected at 72 hr.
In addition to imaging Oil-Red-O stained plates, the replication attempt will quantify the
amount of Oil-Red-O staining spectrophotometrically.

Provisions for quality control
All data obtained from the experiment - raw data, data analysis, control data and quality control
data - will be made publicly available, either in the published manuscript or as an open access dataset available on the Open Science Framework (https://osf.io/vfsbo/).
.
.
.
.

Sequence files and agarose gel images confirming vector identity and integrity
Ponceau stains confirming protein transfer to membranes
STR profiling and mycoplasma testing results
Absorbance data for RNA and cDNA

Protocol 3: Assessing the role of KDM4C on differentiation of 3T3-L1
cells
This protocol describes how to treat 3T3-L1 cells with an siRNA against the histone demethylase
KDM4C, whose activity is inhibited by 2HG, and assess the effect of loss of KDM4C activity on methylation and differentiation, as seen in Figure 4D and Supplemental Figure 8.

Sampling
.

.

.

This experiment will be repeated 3 times for a minimum power of 80%. The Western blot
data is qualitative, thus to determine an appropriate number of replicates to initially perform,
sample sizes based on a range of potential variance was determined.
 See Power calculations for details.
Each experiment consists of five cohorts:
 Cohort 1: 3T3-L1 cells treated with scramble control siRNAs
 Cohort 2: 3T3-L1 cells treated with siRNAs #1 against KDM4C
 Cohort 3: 3T3-L1 cells treated with siRNAs #2 against KDM4C
 Cohort 4: 3T3-L1 cells treated with siRNAs #3 against KDM4C
 Cohort 5: untreated 3T3-L1 cells [additional control]
Each cohort is induced to differentiate, followed by:
 Assessment of methylation by Western blot for:
&
Anti-KDM4C
&
Anti-H3K9me3
&
Anti-H3
&
Anti-b-actin
 Assessment of differentiation by Oil-Red-O staining

Materials and reagents
Reagent

Type

Manufacturer

Catalog #

Comments

3T3-L1 cells

Cell line

ATCC

CL-173

Original source unspecified

DMEM

Cell culture

Corning

15013 CV

Replaces original from Invitrogen

FBS

Cell culture

CellGro

10437-028

Original cat # unspecified

Continued on next page
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Continued
Reagent

Type

Manufacturer

Catalog #

Comments

KDM4C siRNA #1

Nucleic acid

Synthesis left to the discretion of the replicating lab

KDM4C siRNA #2

Nucleic acid

Synthesis left to the discretion of the replicating lab

KDM4C siRNA #3

Nucleic acid

Synthesis left to the discretion of the replicating lab

Scrambled control siRNA

Nucleic acid

Dharmacon

D-001810-01-20

Lipofectamine RNAiMAX

Cell culture

Invitrogen

13778-030

Original cat# unspecified

isobutylmethylxanthine

Inhibitor

Sigma

I5879

Original cat# unspecified

dexamethasone

Chemical

Sigma

D4902

Original cat# unspecified

insulin

Growth factor

Sigma

I3536

Original cat# unspecified

Troglitazone

Chemical

Sigma

T2573

Original cat# unspecified

RIPA buffer

Cell culture

Millipore

20188

Original source unspecified

Nitrocellulose membrane

Western blot reagent

Life Technologies

LC2006

Original source unspecified
Original unspecified

Ponceau stain

Chemical

Sigma

P7170

Mouse IgG2a monoclonal anti-b-actin

Antibody

Sigma

A5316

Rabbit IgG monoclonal anti-H3

Antibody

Cell Signaling Technology

4499

Rabbit polyclonal anti-H3K9me3

Antibody

Abcam

Ab8898

Rabbit polyclonal anti-KDM4C

Antibody

Abcam

Ab85454

Oil-Red-O

Chemical

Sigma

O1391

Original source unspecified

paraformaldehyde

Chemical

Tousimis

1008A

Original source unspecified

Procedure
Note: 3T3-L1 cells are maintained in DMEM with 10% FBS at 37˚C/5% CO2. All cells will be sent for
STR profiling and mycoplasma testing.
.

Transfect with 3T3-L1 cells with siRNAs against KDM4C:
1. Plate out equal densities of single cell suspensions of 3T3-L1 cells in #6-well plates.
a. *Optimize the number of cells to plate per well.
b. Plate out two plates per siRNA pool (control vs. siKDM4C).
i. One will be harvested on Day 3 of differentiation for Western blot analysis.
ii. One will be used on Day 7 of differentiation for Oil-Red-O analysis.
2. Transfect with the following siRNAs at a final concentration of 40 nM using Lipofectamine
RNAiMAX according to the manufacturer’s instructions.

1
2

3

.

.

.

Sense

5’-GCUUGAAUCUCCCAAGAUATT-3’

Antisense

5’-UAUCUU GGGAGAUUCAAGCTT-3’

Sense

5’-CAAAGUAUCUUGGAUCAAATT-3’

Antisense

5’-UUUGAUCCAAGAUACUUUGCC-3’

Sense

5’-GAGGAGUU UCGGGAGUUCAACAAAU-3’

Antisense

5’-AUUUGUUGAACUCCCGAA ACUCCUC-3’

a. Transfect control wells with a scrambled control siRNA.
b. Also plate control wells with no transfection.
3. Incubate for 3 days.
Induce differentiation of control siRNA and antisense siRNA transduced 3T3-L1 cells as specified in Protocol 2 Step 6.
3 days after differentiation, harvest one plate from each treatment and prepare whole cell
lysates as specified in Protocol 2 Step 7.
Perform Western blot analysis on all whole cell lysates from Day 3 as described in Protocol 2
Step 7.
1. Probe with:
a. Anti-KDM4C
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.

.

b. Anti-H3K9me3
c. Anti-H3
d. Anti-b-actin
2. Quantify band intensities with ImageJ.
a. Normalize H3K9me3 band intensities to total H3.
b. Normalize KDM4C band intensities to ß-actin.
At Day 7 of differentiation, assess level of differentiation by Oil-Red-O staining as specified in
Protocol 2 Step 8.
1. Image wells and quantify Oil-Red-O expression.
Repeat experiment an additional two times.

Deliverables
.

.

Data to be collected:
 Whole gel images of all Western blots with ladder (as seen in the top of Figure 4D)
 Images of Oil-Red-O stained wells (as seen in the bottom half of Figure 4D)
Quantification of Oil-Red-O staining at Day 7 of differentiation (compare to Supplemental
Figure 8B)

Confirmatory analysis plan
.

.

Statistical Analysis of the Replication Data:
Note: At the time of analysis we will calculate Pearson’s r to check for correlation between
the two dependent variables, normalized intensities measured for KDM4C and H3K9me3, for
the Western blot data. We will also perform the Shapiro-Wilk test and generate a quantilequantile plot to assess the normality of the Western blot and Oil-Red-O data. We will also
perform Levene’s test to assess homoscedasticity. If the data appears skewed we will perform a log transformation in order to proceed with the proposed statistical analysis. If this is
not possible we will perform the equivalent non-parametric test listed in Power Calculations
for this protocol.
 Quantification of Oil-Red-O staining:
&
One way ANOVA (one dependent variable is the A500 readings; four independent
variables are the control and three KDM4C siRNA sequences) with the following
planned comparisons using Bonferroni’s correction:
. Control siRNA compared to KDM4C siRNA #1
. Control siRNA compared to KDM4C siRNA #2
. Control siRNA compared to KDM4C siRNA #3 [additional exploratory analysis]
 Western blot:
&
One-way MANOVA (two dependent variables are the normalized intensities measured for KDM4C and H3K9me3; four independent variables are the control and
three KDM4C siRNA sequences) with the following planned comparisons using
Bonferroni’s correction:
. H3K9me3 levels:
 Control siRNA compared to KDM4C siRNA #1
 Control siRNA compared to KDM4C siRNA #2
 Control siRNA compared to KDM4C siRNA #3
. KDM4C levels (QC):
 Control siRNA compared to KDM4C siRNA #1
 Control siRNA compared to KDM4C siRNA #2
 Control siRNA compared to KDM4C siRNA #3
Meta-analysis of original and replication attempt effect sizes:
 Oil-Red-O staining for siRNA #1 and #2:
&
This replication attempt will perform the statistical analysis listed above, compute
the effects sizes, compare them against the reported effect size in the original
paper and use a meta-analytic approach to combine the original and replication
effects, which will be presented as a forest plot.
. There is no originally reported data from siRNA #3, therefore it will not be
included.
 Western Blot:
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&

The replication data will be presented as a mean with 95% confidence intervals and
will include the original data point, calculated directly from the representative
image, as a single point on the same plot for comparison.

Known differences from the original study
The replication will perform the Oil-Red-O quantification for all three siRNAs, not just #1 and #2
as presented in Supplemental Figure 8.

Provisions for quality control
All data obtained from the experiment - raw data, data analysis, control data and quality control
data - will be made publicly available, either in the published manuscript or as an open access dataset available on the Open Science Framework (https://osf.io/vfsbo/).
.
.

Ponceau stains confirming protein transfer to membranes
STR profiling and mycoplasma testing results

Power calculations
Note: details of all power calculations can be found at https://osf.io/rb32p/

Protocol 1
Summary of original data
Note: data estimated from published figures.
Supplemental Figure 1: normalized WB band intensity
(normalized to Vector)

Mean

SD

N

IDH1WT

H3K9me2

1.7

0.8

3

H3K9me3

1

0.2

3

K3K4me3

1.2

0.6

3

H3K27me3

0.4

0.3

3

H3K36me3

1.2

0.4

3

H3K27me2

0.8

0.4

3

H3K9me2

7.9

2.5

3

H3K9me3

4.1

1.2

3

R132H

IDH1

WT

IDH2

IDH2R172K
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K3K4me3

3.4

0.8

3

H3K27me3

2.5

0.5

3

H3K36me3

1.7

0.8

3

H3K27me2

4.7

2.5

3

H3K9me2

3.2

1.1

3

H3K9me3

2.1

1.2

3

K3K4me3

1.9

0.3

3

H3K27me3

1.9

0.8

3

H3K36me3

1.4

0.4

3

H3K27me2

1.5

0.9

3

H3K9me2

11.4

3.8

3

H3K9me3

4.9

1.6

3

K3K4me3

4

1.4

3

H3K27me3

3.6

1.6

3

H3K36me3

1.8

0.7

3

H3K27me2

5.4

3.7

3
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Figure 1B: 2HG/glutamate ratios
Mean

Assumed N

IDH1

0.005

3

IDH1R132H

0.052

3

IDH2

0.023

3

IDH2R172K

1.56

3

WT

WT

Test family
.

.

Western blot; Figure 1B/Supplemental Figure 1A:
Note: Since we do not have the raw data, we were unable to perform power calculations
using a MANOVA. We are approximating sample sizes with corrected one-way ANOVAs for
each DV (normalized histone methylations).
. Bonferroni-corrected one-way ANOVAs (one per DV) followed by Bonferroni corrected
planned comparisons:
&
Wild-type IDH1 compared to IDH1R132H, collapsed across all histone lysine
methylations.
&
Wild-type IDH2 compared to IDH2R172K, collapsed across all histone lysine
methylations.
. Note: Only H3K9me2 is being included since this is the histone modification
with the largest effect size reported. A correlation among all the histone methylations will also be performed prior to performing the proposed analysis plan.
2HG/glutamate ratios; Figure 1B:
 One-way ANOVA followed by Bonferroni-corrected pairwise comparisons for the
following:
&
IDH1WT compared to IDH1R132H, for H3K9me2
&
IDH2WT compared to IDH2R172K, for H3K9me2

Power calculations
.

.
.

Power calculations were performed using R software (version 3.2.2) (R Core Team, 2015)
and G*Power (version 3.1.7) (Faul et al., 2007)
Partial h2 calculated as in Lakens (2013)
Western blot calculations:
. Note: Due to the large variance, these parametric tests are only used for comparison purposes. The sample size is based on the non-parametric tests also listed. For the ANOVA
a Kruskal-Wallis would be performed as the non-parametric alternative, which would
require an ~15% increase in sample size calculated for the parametric test listed.

One-way ANOVA: a=0.00833, 4 groupsa
DV
H3K9me2

F(3,8)
10.486

Partial h2
0.79726

Effect size f
1.98302

A priori power

Total Sample Size

1

121

1

92.1%

H3K9me3

7.0274

0.72492

1.62335

96.4%

161

H3K4me3

6.6197

0.71284

1.57556

95.1%1

161

1

161

H3K27me3

6.0339

0.69351

1.50423

92.7%

H3K36me3

0.6276

0.19051

1.06125

90.2%

24

H3K79me2

3.0033

0.52969

1.079842

80.0%2

24

1

With 6 samples per group (24 total), achieved power is 99.9%.
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2

Since the original effect size will not be detectable with the proposed sample size, this is the effect size that can

be detected at 80% power with the given sample size. The original effect size was 0.48512.

Planned contrasts; two-tailed t-test: a=0.004167
Group 1

Group 2

Effect size d

A priori power

n/group

IDH1WT

IDH1R132H

3.34039

84.9%1

51

WT

R172K

2.93138

87.3%

6

A priori power

n/group

IDH2

IDH2

Planned contrasts; two-tailed Wilcoxon-Mann-Whitney: a=0.025
Group 1

Group 2

WT

IDH1

3.34039

80.9%

52

R172K

2.93138

84.0%

6

IDH1

WT

IDH2

Effect size d

R132H

IDH2

1

With 6 samples per group, achieved power is 95.3%.

2

With 6 samples per group, achieved power is 93.4%.

.

2

2HG/glutamate ratio calculations:
. Note: The original data does not indicate the error associated with multiple biological
replicates. To identify a suitable sample size, power calculations were performed using
different levels of relative variance.

2%; one-way ANOVA: a=0.05, 4 groups
F(3,8)

Partial h2

Effect size f

A priori power

Total Sample Size

7240.7

0.99963

52.11901

99.9%

8

Planned comparisons; 2-tailed t-test: a=0.025
Group 1 versus

Effect size d

A priori power

n per group

IDH1

R132H

IDH1

63.6182

99.9%

2

IDH2WT

IDH2R172H

69.6606

99.9%

2

WT

Group 2

15%; one-way ANOVA: a=0.05, 4 groups
F(3,8)

Partial h2

Effect size f

A priori power

Total Sample Size

128.72

0.97970

6.94772

99.9%

8

Planned comparisons; 2-tailed t-test: a=0.025
Group 1 versus

Effect size d

A priori power

n per group

IDH1

R132H

IDH1

8.48242

83.5%

2

IDH2WT

IDH2R172H

9.28808

88.4%

2

WT

Group 2

28%; one-way ANOVA: a=0.05, 4 groups
F(3,8)

Partial h2

Effect size f

A priori power

Total Sample Size

36.942

0.93268

3.72201

99.9%

8

Planned comparisons; 2-tailed t-test: a=0.025
Group 1 versus

Group 2

Effect size d

A priori power

n per group

IDH1WT

IDH1R132H

4.54415

92.4%

3

WT

R172H

4.97576

95.9%

3

IDH2

IDH2
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40%; one-way ANOVA: a=0.05, 4 groups
F(3,8)

Partial h2

Effect size f

A priori power

Total Sample Size

18.102

0.87160

2.60542

96.0%

8

Planned comparisons; 2-tailed t-test: a=0.025
Group 1 versus

Effect size d

A priori power

n per group

IDH1

R132H

IDH1

3.18091

89.6%

4

IDH2WT

IDH2R172H

3.48303

94.2%

4

WT

Group 2

In order to produce quantitative replication data, we will run the experiment six times. Each time
we will quantify the 2HG/glutamate ratio. We will determine the standard deviation across the biological replicates and combine this with the reported value from the original study to simulate the
original effect size. We will use this simulated effect size to determine the number of replicates necessary to reach a power of at least 80%. We will then perform additional replicates, if required, to
ensure that the experiment has more than 80% power to detect the original effect.

Protocol 2
Summary of original data
Note: data estimated from published figures.

Figure 2A: 2HG/glutamate ratio

Assumed N
Mean

Vector

0.1

3

IDH1R172K

5.3

3

0.1

3

WT

IDH2

Figure 2D: Relative expression of adipocyte markers
Pparg
Vector
IDH2WT
R172K

IDH2

Mean

IDH2WT
IDH2R172K

Adipoq

N

Day 0

1.45

0.823

3

Day 4

13.992

0.816

3

Day 0

2.521

1.076

3

Day 4

10.966

0.879

3

Day 0

1.134

0.823

3

Day 4

4.223

0.941

3

Mean

SD

N

Cebpa
Vector

SD

Day 0

1.123

0.421

3

Day 4

3.053

1.188

3

Day 0

1.93

0.456

3

Day 4

4.807

0.565

3

Day 0

0.667

0.491

3

Day 4

0.246

0.21

3

Mean

SD

N

Continued on next page
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Vector
IDH2WT
R172K

IDH2

Day 0

0

58.621

3

Day 4

572.414

193.103

3

Day 0

0

58.621

3

Day 4

448.276

86.207

3

Day 0

0

58.621

3

Day 4

41.379

27.586

3

Test family
.

.

2HG/glutamate ratios; Figure 2A bottom:
 One way ANOVA followed by Fisher’s LSD for the following comparison:
&
IDH2WT vs. IDH2R172K
qRT-PCR; Figure 2D:
Note: Since we did not have the raw data, we were unable to perform power calculations
using a MANOVA. We are approximating the sample sizes with corrected one-way ANOVAs
for each DV (gene).
 Bonferroni-corrected one-way ANOVAs (one per gene) followed by Bonferroni corrected
comparisons for Day 4 timepoints:
&
IDH2R172Kcompared to vector for each gene (3 comparisons total)
&
IDH2R172Kcompared to IDH2WT for each gene (3 comparisons total)

Power calculations
.

.
.

Power calculations were performed using R software (version 3.2.2) (R Core Team, 2015)
and G*Power (version 3.1.7) (Faul et al., 2007)
Partial h2 calculated as in Lakens (2013)
2HG/glutamate ratios:
 Note: The original data does not indicate the error associated with multiple biological
replicates. To identify a suitable sample size, power calculations were performed using
different levels of relative variance.

2%; one-way ANOVA: a=0.05, 3 groups
F(2,6)

Partial h2

Effect size f

A priori power

Total Sample Size

7214.5

0.99958

49.0188

99.9%

6

Planned comparisons; two-tailed t-test: a=0.05
Group 1 versus

Group 2

Effect size d

A priori power

n per group

IDH2R172H

IDH2WT

84.9383

99.9%

2

15%; one-way ANOVA: a=0.05, 3 groups
F(2,6)

Partial h2

Effect size f

A priori power

Total Sample Size

128.26

0.97715

6.53866

99.9%

6

Planned comparisons; two-tailed t-test: a=0.05
Group 1 versus

Group 2

Effect size d

A priori power

n per group

IDH2R172H

IDH2WT

11.3252

99.8%

2

Effect size f

A priori power

Total Sample Size

28%; one-way ANOVA: a=0.05, 3 groups
F(2,6)

Partial h2
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36.809

0.92464

3.50285

98.5%

6

Effect size d

A priori power

n per group

6.06704

84.2%

2

Planned comparisons; two-tailed t-test: a=0.05
Group 1 versus
R172H

IDH2

Group 2
WT

IDH2

40%; one-way ANOVA: a=0.05, 3 groups
F(2,6)

Partial h2

Effect size f

A priori power

Total Sample Size

18.036

0.85739

2.45194

85.1%

6

Planned comparisons; two-tailed t-test: a=0.05
Group 1 versus

Group 2

Effect size d

A priori power

n per group

IDH2R172H

IDH2WT

4.24688

96.6%

3

In order to produce quantitative replication data, we will run the experiment five times. Each time
we will quantify the 2HG/glutamate ratio. We will determine the standard deviation across the biological replicates and combine this with the reported value from the original study to simulate the
original effect size. We will use this simulated effect size to determine the number of replicates necessary to reach a power of at least 80%. We will then perform additional replicates, if required, to
ensure that the experiment has more than 80% power to detect the original effect.
.

qRT-PCR:
 Note: Due to the large variance, these parametric tests are only used for comparison purposes. The sample size is based on the non-parametric tests also listed. For the ANOVA
a Kruskal-Wallis would be performed as the non-parametric alternative, which would
require an ~15% increase in sample size calculated for the parametric test listed.

Pparg
One-way ANOVA: a=0.0167, 3 groups
F(2,6)

Partial h2

Effect size f

A priori power

Total Sample
Size

96.854

0.96996

5.68195

99.5%1

61

Planned comparisons; two-tailed t-test: a=0.0083
Group 1 versus

Group 2

Effect size d

A priori power

n per group

IDH2R172H

Vector

11.0921

99.9%2

32

IDH2R172H

IDH2WT

7.40559

98.6%2

32

A priori power

n per group

Planned comparisons; two-tailed Wilcoxon-Mann-Whitney: a=0.0083
Group 1 versus

Group 2

R172H

IDH2

Effect size d

Vector

R172H

11.0921

WT

IDH2

IDH2

7.40559

1

With 5 samples per group (15 total), achieved power is 99.9%.

2

With 5 samples per group, achieved power is 99.9%.

2

32

2

32

99.9%

96.9%

Cebpa
One-way ANOVA: a=0.0167, 3 groups
F(2,6)

Partial h2

Effect size f

A priori power

Total Sample Size

26.843

0.89947

5.68195

90.5%1

61

Planned comparisons; two-tailed t-test: a=0.0083
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Group 1 versus

Group 2

Effect size

A priori power

IDH2

Vector

3.29048

91.6%

5

IDH2R172H

IDH2WT

10.7011

99.9%2

32

R172H

n per group

Planned comparisons; two-tailed Wilcoxon-Mann-Whitney: a=0.0083
Group 1 versus

Group 2

Effect size d

A priori power

n per group

IDH2R172H

Vector

3.29048

89.0%

5

R172H

IDH2

WT

IDH2

10.7011

1

With 5 samples per group (15 total), achieved power is 99.9%.

2

With 5 samples per group, achieved power is 99.9%.

2

99.9%

32

A priori power

Total Sample Size

Adipoq
One-way ANOVA: a=0.0167, 3 groups
F(2,6)
15.269

Partial h2
0.83579

Effect size f
2.25603

1

91

96.3%

Planned comparisons; two-tailed t-test: a=0.0083
Group 1 versus

Group 2

Effect size

A priori power

n per group

IDH2R172H

Vector

3.85001

87.8%2

42

IDH2R172H

IDH2WT

6.35752

94.5%3

33

A priori power

n per group

Planned comparisons; two-tailed Wilcoxon-Mann-Whitney: a=0.0083
Group 1 versus
R172H

IDH2

R172H

IDH2
1

Group 2
Vector
WT

IDH2

Effect size d
3.85001
6.35752

4

44

3

33

84.0%

90.8%

With 5 samples per group (15 total), achieved power is

99.9%.
2

With 5 samples per group, achieved power is 97.9%.

3

With 5 samples per group, achieved power is 99.9%.

4

With 5 samples per group, achieved power is 96.8%.

Protocol 3
Summary of original data
Note: data estimated from published figures.

Band intensity
(normalized to H3)

Figure 4D and S8A: Western Blot
KDM4C

H3K9me3

1
2

Control siRNA

1

KDM4C siRNA #1

0.50971

KDM4C siRNA #2

0.27671

KDM4C siRNA #3

0.02492

Control siRNA

1

KDM4C siRNA

0.36952

These values were normalized to ß-Actin as seen in Supplemental Figure 8A.
These values were normalized to total H3 as seen in Figure 4D. Also there is no data for siRNAs #1 and #2. We

have assumed similar values for siRNA #3 for the purposes of these calculations.
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Supplemental Figure 8B: Oil-Red-O quantification

Mean

SD

N

Control

1.06

0.03

3

siRNA #1

0.42

0.15

3

siRNA #2

0.69

0.09

3

siRNA #31

0.69

0.09

3

1

There is no data for siRNA #3. We have assumed similar values as siRNA #2 for the purposes of these
calculations.

Test family
.

.

Western blot; Figure 4D and S8A:
Note: Since we did not have the raw data, we were unable to perform power calculations
using a MANOVA. We are approximating the sample sizes with corrected one-way ANOVAs
for each DV (normalized protein).
 One-way ANOVAs followed by Bonferroni corrected comparisons:
&
H3K9me3 levels in control siRNA compared to each KDM4C siRNA (3 comparisons
total)
&
KDM4C levels in control siRNA compared to each KDM4C siRNA (3 comparisons
total)
Quantification of Oil-Red-O staining; Figure S8B:
 One way ANOVA followed by Bonferroni corrected comparisons:
&
Control siRNA compared to KDM4C siRNA #1
&
Control siRNA compared to KDM4C siRNA #2
&
Control siRNA compared to KDM4C siRNA #3

Power calculations
.

.
.

Power calculations were performed using R software (version 3.2.2) (R Core Team, 2015)
and G*Power (version 3.1.7) (Faul et al., 2007).
Partial h2 calculated as in Lakens (2013).
Western Blot
 Note: The original data does not indicate the error associated with multiple biological
replicates. To identify a suitable sample size, power calculations were performed using
different levels of relative variance.

2%; One-way ANOVA: a=0.025, 4 groups a
DV

F(3,8)

Partial h2

Effect size f

Power

Total sample
size

H3K9me3

2114.7

0.99874

28.161

99.9%

8

KDM4C

3865.5

0.99931

38.073

99.9%

8

Effect size d

A priori
power

n per group

Planned comparisons; two-tailed t-test: a=0.0083
DV
H3K9me3

KDM4C

Group 1 versus

Group 2

Control

KDM4C #1

53.099

99.9%

2

Control

KDM4C #2

53.099

99.9%

2

Control

KDM4C #3

53.099

99.9%

2

Control

KDM4C #1

42.407

99.9%

2

Control

KDM4C #2

62.552

99.9%

2

Control

KDM4C #3

84.335

99.9%

2
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15%; One-way ANOVA: a=0.025, 4 groups
DV

F(3,8)

Partial h2

Effect size f

Power

Total sample size

H3K9me3

37.595

0.93377

3.7547

99.2%

8

KDM4C

68.72

0.96264

5.0764

99.9%

8

Planned comparisons; two-tailed t-test: a=0.0083
DV

Group 1 versus

Group 2

Effect size d

A priori power

n per group

H3K9me3

Control

KDM4C #1

7.0800

97.8%

3

Control

KDM4C #2

7.0800

97.8%

3

KDM4C

Control

KDM4C #3

7.0800

97.8%

3

Control

KDM4C #1

5.6543

88.5%

3

Control

KDM4C #2

8.3403

99.6%

3

Control

KDM4C #3

11.245

99.9%

3

Effect size f

Power

Total sample size

28%; One-way ANOVA: a=0.025, 4 groups
DV

F(3,8)

Partial h2

H3K9me3

10.789

0.80182

2.0114

98.7%

12

KDM4C

19.722

0.88089

2.7195

89.2%

8

Planned comparisons; two-tailed t-test: a=0.0083
DV

Group 1 versus

Group 2

Effect size d

A priori power

n per group

H3K9me3

Control

KDM4C #1

3.7928

86.8%

4

Control

KDM4C #2

3.7928

86.8%

4

Control

KDM4C #3

3.7928

86.8%

4

Control

KDM4C #1

3.0291

85.9%

5

Control

KDM4C #2

4.4680

95.8%

4

Control

KDM4C #3

6.0240

92.1%

3

KDM4C

40%; One-way ANOVA: a=0.025, 4 groups
DV

F(3,8)

Partial h2

Effect size f

Power

Total sample size

H3K9me3

5.2868

0.66472

1.4080

80.2%

12

KDM4C

9.6637

0.78373

1.9037

97.6%

12

Planned comparisons; two-tailed t-test: a=0.0083
DV

Group 1 versus

Group 2

Effect size d

A priori power

n per group

H3K9me3

Control

KDM4C #1

2.6550

87.2%

6

Control

KDM4C #2

2.6550

87.2%

6

KDM4C

Control

KDM4C #3

2.6550

87.2%

6

Control

KDM4C #1

2.1204

85.6%

8

Control

KDM4C #2

3.1276

88.3%

5

Control

KDM4C #3

4.2168

93.3%

4

In order to produce quantitative replication data, we will run the experiment three times. Each
time we will quantify band intensity. We will determine the standard deviation of band intensity
across the biological replicates and combine this with the reported value from the original study to
simulate the original effect size. We will use this simulated effect size to determine the number of
replicates necessary to reach a power of at least 80%. We will then perform additional replicates, if
required, to ensure that the experiment has more than 80% power to detect the original effect.
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.

Oil-Red-O staining:
 Note: Due to the large variance, these parametric tests are only used for comparison purposes. The sample size is based on the non-parametric tests also listed. For the ANOVA
a Kruskal-Wallis would be performed as the non-parametric alternative, which would
require an ~15% increase in sample size calculated for the parametric test listed.

One-way ANOVA: a=0.05, 4 groups
F(3,8)

Partial eta2

Effect size f

Power

Total Sample Size

20.939

0.88703

2.8022

97.8%1

81

1

With 3 samples per group (12 total), achieved power is 99.9%.

Planned comparisons; two-tailed Wilcoxon-Mann-Whitney: a=0.0167
Power Calculations
Group 1

Group 2

Effect size d

Power

n/group

Control

KDM4C #1

5.9168

96.9%

3

Control

KDM4C #2

5.5156

93.3%

3

Control

KDM4C #3

5.5156

93.3%

3

Planned comparisons; two-tailed t-test: a=0.0167
Group 1

Group 2

Effect size d

Power

n/group

Control

KDM4C #1

5.9168

97.7%

3

Control

KDM4C #2

5.5156

95.6%

3

Control

KDM4C #3

5.5156

95.6%

3
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Godley LA, Delwel R, Valk PJM, Thompson CB, Levine RL, Melnick A. 2010. Leukemic IDH1 and IDH2
mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic
differentiation. Cancer Cell 18:553–567. doi: 10.1016/j.ccr.2010.11.015
Kernytsky A, Wang F, Hansen E, Schalm S, Straley K, Gliser C, Yang H, Travins J, Murray S, Dorsch M, Agresta S,
Schenkein DP, Biller SA, Su SM, Liu W, Yen KE. 2015. IDH2 mutation-induced histone and DNA
hypermethylation is progressively reversed by small-molecule inhibition. Blood 125:296–303. doi: 10.1182/
blood-2013-10-533604
Krell D, Mulholland P, Frampton AE, Krell J, Stebbing J, Bardella C. 2013. IDH mutations in tumorigenesis and
their potential role as novel therapeutic targets. Future Oncology (London, England) 9:1923–1935. doi: 10.
2217/fon.13.143
Lakens D. 2013. Calculating and reporting effect sizes to facilitate cumulative science: a practical primer for ttests and ANOVAs. Frontiers in Psychology 4:863. doi: 10.3389/fpsyg.2013.00863
Londono Gentile T, Lu C, Lodato PM, Tse S, Olejniczak SH, Witze ES, Thompson CB, Wellen KE. 2013. DNMT1
is regulated by ATP-citrate lyase and maintains methylation patterns during adipocyte differentiation.
Molecular and Cellular Biology 33:3864–3878. doi: 10.1128/MCB.01495-12
Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, Edwards CR, Khanin R, Figueroa ME, Melnick A,
Wellen KE, O’Rourke DM, Berger SL, Chan TA, Levine RL, Mellinghoff IK, Thompson CB. 2012. IDH mutation
impairs histone demethylation and results in a block to cell differentiation. Nature 483:474–478. doi: 10.1038/
nature10860
McKenney AS, Levine RL. 2013. Isocitrate dehydrogenase mutations in leukemia. The Journal of Clinical
Investigation 123:3672–3677. doi: 10.1172/JCI67266
Sasaki M, Knobbe CB, Munger JC, Lind EF, Brenner D, Brüstle A, Harris IS, Holmes R, Wakeham A, Haight J,
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